Press Releases

INCLINE VILLAGE, Nev. , Dec. 10, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the fourth quarter ending December 31, 2014 , of approximately $158 million , as compared with actual revenue of $112 million for the fourth quarter of 2013, an

INCLINE VILLAGE, Nev. , Dec. 4, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for the: 3.75% Convertible Senior Notes due May 1, 2015 ( May 2015 Notes), is 171.1768 shares of common stock per $1,000 principal amount or approximately

INCLINE VILLAGE, Nev. , Nov. 18, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that in connection with the acquisition of Durata Therapeutics, Inc. by Actavis, PDL has received approximately $42.7 million in connection with the termination of PDL's credit agreement

INCLINE VILLAGE, Nev. , Nov. 14, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company has received $30.3 million , in addition to previously received revenue interest payments, to conclude PDL's revenue interest agreement with AxoGen, Inc. (NASDAQ: AXGN).

INCLINE VILLAGE, Nev. , Nov. 12, 2014 /PRNewswire/ --   PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that company management will present at the Jefferies 2014 Global Healthcare Conference next week in London . The presentation, which will be webcast, will occur on November 19, 2014 at

-Third Quarter Revenues Increase 64 Percent -

INCLINE VILLAGE, Nev. , Nov. 6, 2014 /PRNewswire/ -- PDL BioPharma ("PDL") (Nasdaq: PDLI) announced today that it has acquired a portion of the University of Michigan's ("U-M") worldwide royalty interest in Cerdelga™ (eliglustat) for $65.6 million .  Cerdelga, an oral therapy for adult patients

INCLINE VILLAGE, Nev. , Nov. 3, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its third quarter 2014 financial results for the period ended September 30, 2014 , on Monday, November 10, 2014 , after market close.

INCLINE VILLAGE, Nev. , Oct. 8, 2014 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI), today announced the appointment of PricewaterhouseCoopers LLP (" PwC ") as its independent registered public accounting firm. PwC will commence work immediately, beginning with their

INCLINE VILLAGE, Nev. , Oct. 6, 2014 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI), today announced two enhancements to the company's management team.  Danny Hart , who has served in the position of deputy general counsel, assistant secretary and corporate counsel since 2010, has been

INCLINE VILLAGE, Nev. , Sept. 23, 2014 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI), has been informed of a class action lawsuit filed against the company that alleges violations of federal securities laws. The company disputes the allegations in the complaint and will vigorously

INCLINE VILLAGE, Nev. , Sept. 17, 2014 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) was orally notified by its independent registered accounting firm, Ernst & Young LLP ("EY") that it was resigning effective September 11, 2014 . The resignation was confirmed in a letter delivered to

INCLINE VILLAGE, Nev. , Sept. 15, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the September 12, 2014 , regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of September 5, 2014 , the record date.

INCLINE VILLAGE, Nev. , Sept. 9, 2014 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the third quarter ending September 30, 2014 , of approximately $165 million , as compared with actual revenue of $100.2 million for the third quarter of 2013, an

INCLINE VILLAGE, Nev. , Sept. 4, 2014 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for the:  3.75% Convertible Senior Notes due May 1, 2015 ( May 2015 Notes), is 167.9812 shares of common stock per $1,000 principal amount or